Oncopeptides AB (ONCO) Stock Statistics & Valuation Metrics

Oncopeptides AB has a market cap or net worth of kr803.14M. The enterprise value is kr595.78M.

Oncopeptides AB has 381,357,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oncopeptides AB’s return on equity (ROE) is 4.24 and return on invested capital (ROIC) is -230.36%.

The current PE Ratio of Oncopeptides AB is ―. Oncopeptides AB’s PEG ratio is 0.12.

In the last 12 months, Oncopeptides AB had revenue of 71.12M and earned -249.59M in profits. Earnings per share was -1.10.

In the last 12 months, operating cash flow was -188.56M and capital expenditures 0.00, giving a free cash flow of -188.56M billion.

Oncopeptides AB pays an annual dividend of ―, resulting in a dividend yield of ―

Oncopeptides AB upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).

Oncopeptides AB as a current ratio of 2.63, with Debt / Equity ratio of 542.28%

In the past 12 months, Oncopeptides AB has paid 1.42M in taxes.

Oncopeptides AB EV to EBITDA ratio is -5.24, with an EV/FCF ratio of -5.15.

Oncopeptides AB has kr157.61M in cash and marketable securities with kr135.17M in debt, giving a net cash position of kr22.44M billion.

Gross margin is 96.40%, with operating margin of -317.62%, and net profit margin of -350.94%.

The average price target for Oncopeptides AB is ―, which is 11.43% higher than the current price. The consensus rating is ―